Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 1,890 Shares of Stock

February 5, 2026 by InsiderTrades.com

Key Points

Director Peter Thompson sold 29,063 shares on Feb. 3 at an average price of $44.58 for about $1.30 million, trimming his position by 0.82% to 3,530,702 shares (≈$157.4 million), according to an SEC filing.
Stock and analyst context: Sionna trades near its one‑year high with a $1.84 billion market cap, a 50‑day/200‑day SMA of $41.40/$32.80, and a consensus rating of "Moderate Buy" with an average target price of $45.43.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Peter Thompson sold 1,890 shares of Sionna Therapeutics stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $44.57, for a total transaction of $84,237.30. Following the sale, the director directly owned 3,559,765 shares in the company, valued at approximately $158,658,726.05. The trade was a 0.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Sionna Therapeutics Price Performance

NASDAQ SION opened at $41.31 on Thursday. The stock has a market capitalization of $1.84 billion and a P/E ratio of -8.48. The firm's 50-day moving average is $41.40 and its two-hundred day moving average is $32.80. Sionna Therapeutics, Inc. has a 12 month low of $7.26 and a 12 month high of $45.00.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Key Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

Positive Sentiment: Broker consensus/price target supports upside vs. recent levels — several brokerages imply further upside with an average target around $45.43, which underpins buyer interest despite near‑term selling pressure. Brokerages Set Sionna Therapeutics, Inc. (NASDAQ:SION) Price Target at $45.43
Neutral Sentiment: Investor event scheduled — Sionna management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit on Feb. 11; the presentation could provide pipeline color or analyst Q&A but contains no new clinical data yet. Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Negative Sentiment: Director Peter A. Thompson sold 29,063 shares on Feb. 3 (avg ~$44.58) and 1,890 shares on Feb. 2 — a modest trim (~0.82% and 0.05% of his holdings) that can create short‑term selling pressure even though he retains a very large stake. SEC Filing: Peter A. Thompson Sales
Negative Sentiment: Orbimed Advisors LLC reported similar sales (29,063 and 1,890 shares at ~ $44.57–$44.58), another liquidity event that can amplify downward moves in the stock near those price levels. SEC Filing: Orbimed Advisors LLC Sales

Analyst Ratings Changes

A number of equities analysts recently commented on SION shares. Lifesci Capital started coverage on Sionna Therapeutics in a report on Tuesday, December 23rd. They set an "outperform" rating and a $60.00 target price for the company. Wall Street Zen upgraded shares of Sionna Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, December 13th. BTIG Research reiterated a "buy" rating and set a $58.00 target price on shares of Sionna Therapeutics in a report on Wednesday, January 14th. Raymond James Financial reaffirmed a "strong-buy" rating and set a $53.00 price objective on shares of Sionna Therapeutics in a research report on Monday, January 5th. Finally, Royal Bank Of Canada reiterated an "underperform" rating and issued a $24.00 target price on shares of Sionna Therapeutics in a report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Sionna Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $45.43.

Get Our Latest Analysis on SION

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. purchased a new stake in Sionna Therapeutics in the first quarter valued at $667,000. Woodline Partners LP acquired a new stake in shares of Sionna Therapeutics in the 1st quarter valued at about $837,000. Aberdeen Group plc grew its stake in Sionna Therapeutics by 27.4% during the 2nd quarter. Aberdeen Group plc now owns 950,547 shares of the company's stock worth $16,492,000 after buying an additional 204,583 shares during the last quarter. Geode Capital Management LLC increased its position in Sionna Therapeutics by 113.4% during the second quarter. Geode Capital Management LLC now owns 289,275 shares of the company's stock worth $5,020,000 after buying an additional 153,712 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Sionna Therapeutics in the second quarter valued at approximately $45,000.

About Sionna Therapeutics

(Get Free Report)

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.